{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T12:41:24Z","timestamp":1710765684148},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41443-024-00838-1","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T08:02:05Z","timestamp":1708329725000},"page":"173-174","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling treatment horizons and contemporary perspectives in Peyronie\u2019s disease \u2013 take home messages from Laurance A. Levine special issue"],"prefix":"10.1038","volume":"36","author":[{"given":"Laurance A.","family":"Levine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"838_CR1","doi-asserted-by":"crossref","unstructured":"Twidwell J, Levine L. Topical treatment for acute phase Peyronie\u2019s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. Int J Impot Res. 2016;28:41\u20135. https:\/\/pubmed.ncbi.nlm.nih.gov\/26700214\/.","DOI":"10.1038\/ijir.2015.22"},{"key":"838_CR2","doi-asserted-by":"publisher","unstructured":"Twidwell J, Mahon J, Tortorelis D, Levine L. Transdermal application of H100 gel to the penile shaft in patients with Peyronie\u2019s disease infiltrates the tunica albuginea. Int J Impot Res. 2024. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00819-w.","DOI":"10.1038\/s41443-023-00819-w"},{"key":"838_CR3","doi-asserted-by":"publisher","unstructured":"Gao D, Shen Y, Tang B, Ma Z, Chen D, Yu X, et al. The 100 most-cited publications on Peyronie\u2019s disease: a bibliometric analysis and visualization study. Int J Impot Res. 2023. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00703-7.","DOI":"10.1038\/s41443-023-00703-7"},{"key":"838_CR4","doi-asserted-by":"publisher","unstructured":"Roadman D, Wang V, Beer A, Levine L. A contemporary assessment of the evaluation and management of patients presenting to a tertiary medical center with Peyronie\u2019s disease. Int J Impot Res. 2023. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00738-w.","DOI":"10.1038\/s41443-023-00738-w"},{"key":"838_CR5","doi-asserted-by":"publisher","unstructured":"Maremanda AP, Du Comb W, Able C, Kohn TP, Unal S, Burnett AL. Erectile dysfunction and Peyronie\u2019s disease diagnosis rates after penile fracture-a retrospective claims database cohort analysis. Int J Impot Res. 2023. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00746-w.","DOI":"10.1038\/s41443-023-00746-w"},{"key":"838_CR6","doi-asserted-by":"publisher","unstructured":"Spirito L, Manfredi C, La Rocca R, Napolitano L, Di Girolamo A, Capece M, et al. Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie\u2019s disease: a retrospective comparative analysis. Int J Impot Res. 2022. Available from: https:\/\/doi.org\/10.1038\/s41443-022-00651-8.","DOI":"10.1038\/s41443-022-00651-8"},{"key":"838_CR7","doi-asserted-by":"publisher","unstructured":"Durukan E, Kraglund R, Rashid SA, Thorkilgaard T, Jensen CFS, Fode M. Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie\u2019s Disease: A retrospective cohort study. Int J Impot Res. 2024. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00810-5.","DOI":"10.1038\/s41443-023-00810-5"},{"key":"838_CR8","doi-asserted-by":"publisher","unstructured":"Ziegelmann M. Is there a new role for oral therapy to treat peyronie\u2019s disease? Commentary on Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie\u2019s Disease: a retrospective comparative analysis. Int J Impot Res. 2023. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00684-7.","DOI":"10.1038\/s41443-023-00684-7"},{"key":"838_CR9","doi-asserted-by":"publisher","unstructured":"Manfredi C, Bologna E, Licari LC. Commentary on \u201cPhosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie\u2019s disease: a retrospective cohort study.\u201d Int J Impot Res. 2023. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00811-4.","DOI":"10.1038\/s41443-023-00811-4"},{"key":"838_CR10","doi-asserted-by":"publisher","unstructured":"Spirito L, Manfredi C, La Rocca R, Napolitano L, Preto M, Di Girolamo A, et al. Long-term outcomes of extracorporeal shock wave therapy for acute Peyronie\u2019s disease: a 10-year retrospective analysis. Int J Impot Res. 2023. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00673-w.","DOI":"10.1038\/s41443-023-00673-w"},{"key":"838_CR11","doi-asserted-by":"publisher","unstructured":"Zugail AS, Alshuaibi M, Lombion S, Beley S. Safety and feasibility of percutaneous needle tunneling with platelet-rich plasma injections for Peyronie\u2019s disease in the outpatient setting: a pilot study. Int J Impot Res. 2023. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00744-y.","DOI":"10.1038\/s41443-023-00744-y"},{"key":"838_CR12","doi-asserted-by":"publisher","unstructured":"\u015eahin A, G\u00fcl M. Commentary on: Safety and feasibility of percutaneous needle tunneling with platelet-rich plasma injections for Peyronie\u2019s disease in the outpatient setting: a pilot study. Int J Impot Res. 2023. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00806-1.","DOI":"10.1038\/s41443-023-00806-1"},{"key":"838_CR13","doi-asserted-by":"crossref","unstructured":"Tsambarlis P, Levine LA. Non surgical management of Peyronie\u2019s disease. Nat Rev Urol. 2019;16:172\u201386. https:\/\/pubmed.ncbi.nlm.nih.gov\/30397330\/.","DOI":"10.1038\/s41585-018-0117-7"},{"key":"838_CR14","doi-asserted-by":"publisher","unstructured":"Razdan S, Zisman A, Valenzuela R. Scrotal approach for tunica expansion procedure (TEP) for penile girth and length restoration during penile prosthesis implantation in patients with penile angulation due to Peyronie\u2019s disease and erectile dysfunction: technique and outcomes. Int J Impot Res. 2022. Available from: https:\/\/doi.org\/10.1038\/s41443-022-00652-7.","DOI":"10.1038\/s41443-022-00652-7"},{"key":"838_CR15","doi-asserted-by":"publisher","unstructured":"Bernstein AP, Loloi J, Hillelsohn J. Comment on: \u201cScrotal approach for tunica expansion procedure (TEP) for penile girth and length restoration in patients with penile angulation due to Peyronie\u2019s disease and erectile dysfunction: technique and outcomes.\u201d Int J Impot Res. 2023. https:\/\/doi.org\/10.1038\/s41443-023-00665-w.","DOI":"10.1038\/s41443-023-00665-w"},{"key":"838_CR16","doi-asserted-by":"crossref","unstructured":"Feng CL, Langbo WA, Anderson LK, Cao D, Bajic P, Amarasekera C, et al. Sub coronal inflatable penile prosthesis implantation: indications and outcomes. J Sex Med. 2023;20:888\u201392. https:\/\/pubmed.ncbi.nlm.nih.gov\/37076135\/.","DOI":"10.1093\/jsxmed\/qdad049"},{"key":"838_CR17","doi-asserted-by":"publisher","unstructured":"Loloi J, Schuppe K, Reddy RV, Rahman F, Bernstein A, Reddy P, et al. A survey of exposure to the use of Xiaflex for the treatment of Peyronie\u2019s disease among United States urology residency programs. Int J Impot Res. 2023. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00781-7.","DOI":"10.1038\/s41443-023-00781-7"},{"key":"838_CR18","doi-asserted-by":"publisher","unstructured":"Ghosh A, Leong JY, Foss H, Ebbott D, Prebay Z, Li M, et al. Evaluating treatment pathways for Peyronie\u2019s disease utilizing the TriNetX research registry. Int J Impot Res. 2023. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00815-0.","DOI":"10.1038\/s41443-023-00815-0"},{"key":"838_CR19","doi-asserted-by":"publisher","unstructured":"Kianian R, Regets KV, Mills JN, Eleswarapu SV \u201cCan we try to avoid surgery first?\u201d-Real-world experience with surgery for Peyronie\u2019s disease in the post-intralesional collagenase setting. Int J Impot Res. 2023. Available from: https:\/\/doi.org\/10.1038\/s41443-023-00713-5.","DOI":"10.1038\/s41443-023-00713-5"},{"key":"838_CR20","doi-asserted-by":"crossref","unstructured":"Bajic P, Wiggins AB, Ziegelmann MJ, Levine LA. Characteristics of Men With Peyronie\u2019s Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes. J Sex Med. 2020;17:1005\u201311. https:\/\/pubmed.ncbi.nlm.nih.gov\/32127330\/.","DOI":"10.1016\/j.jsxm.2020.02.002"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-024-00838-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-024-00838-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-024-00838-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T12:01:57Z","timestamp":1710763317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-024-00838-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["838"],"URL":"https:\/\/doi.org\/10.1038\/s41443-024-00838-1","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"19 February 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}